2.Y. Wu, J. Zhao, J. Hu,etc.388P - Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study[J].ESMO Asia Congress 2022.3. 牛娜.非小细胞肺癌 ＭＥＴ基因...
[7]Lu S, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label,...
[7].Lu S, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label...
[8] Socinski MA, Pennell NA, Davies KD. MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. JCO Precis Oncol. 2021 Apr 13;5:PO.20.00516. [9] Liu SY, Gou LY, Li AN et al. The unique characteristics of...
[3] Lu S, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study[J]. Lancet Respir Med. 2021;9(10):1154-1164. ...
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life. Clin Cancer Res. 2016 Jun 15;22(12):2832-4. doi: 10.1158/1078-0432.CCR-16-0229. Epub 2016 Mar 23. PMID: 27009743; PMCID: PMC4911276.[2] Donavan T. Cheng, et al., Memorial Sloan Kettering-Integrated Mutation ...
[4]Lu S, Fang J, Li X, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study[J]. The Lancet Respiratory Medicine, 20...
本期「In China For Global - MET 新例量」分享 1 例 MET ex14 跳突晚期 NSCLC 患者,采用赛沃替尼 600 mg QD 一线治疗,获得了缩小的疾病稳定(SD),至最后一次随访时无进展生存期(PFS)超 17 个月。该病例由锦州医科大学附属第一医院刘晓梅教授、王玉玺医师提供,并邀请大连医科大学附属第一医院张春霞教授点评...
However, recently mutations which result in the loss of exon 14 (called METex14 skipping) have emerged as novel biomarkers in non-small cell lung carcinomas (NSCLC) to predict for responsiveness to targeted therapy with c-MET inhibitors. Currently, the diverse genomic alterations responsible for ...
研究人员对这1387例患者进行检测,共检测出1393种MET14号外显子跳跃突变,横跨多个功能位点:供体区(donor,42%)、受体区(acceptor,4.7%)、多嘧啶序列(poly-pyrimidine tract,15%)、受体和多嘧啶序列(13%)、D1010(23%)、Y1003(2.1%)和全外显子缺失(whole exon deletions,0.3%)[5]。由此可见MET14号外显子跳跃...